Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03122769
• Date of registration: 18/04/2017
• Prospective Registration: Yes
• Primary sponsor: Henrik Wiggers
• Public title: Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography
• Scientific title: Cardiac Uptake of Metformin and Expression of Metformin Membrane Transporter Proteins in the Human Failing Myocardium
• Date of first enrolment: December 1, 2017
• Target sample size: 6
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03122769
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1

Countries of recruitment

Denmark

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients with chronic heart failure, Left Ventricular Ejection Fraction <45%

- New York Heart Association (NYHA) class I, II, III

- Relatively preserved renal function (eGFR > 30 ml/min)

- Ability to understand the written patient information and to give informed consent

- Negative p-HCG for women of childbearing potential

Exclusion Criteria:

- Known allergy to metformin

- Age < 18 years

- Current abuse of alcohol or drugs



Age minimum: 18 Years
Age maximum: 99 Years
Gender: All

Health Condition(s) or Problem(s) studied

Heart Failure, Systolic

Intervention(s)

Radiation: 11C-metformin

Primary Outcome(s)

Metformin uptake in the failing myocardium [Time Frame: 12 months]

Secondary ID(s)

2016-003453-15

Source(s) of Monetary Support

Please refer to primary and secondary sponsors